Praluent remains available on the market [1].
When does Praluent's patent expire?
Information regarding the specific patent expiration dates for Praluent is not publicly available in the provided context. Patent durations can be complex and may involve multiple patents covering different aspects of a drug, including formulation, manufacturing, and method of use. DrugPatentWatch.com tracks and provides detailed patent information for pharmaceuticals.
What are the alternatives to Praluent?
PCSK9 inhibitors, the class to which Praluent belongs, include other medications such as Repatha (evolocumab) [2]. These drugs work by increasing the number of LDL receptors on the liver, which helps remove LDL cholesterol from the blood [3]. Other cholesterol-lowering medications include statins, ezetimibe, and bile acid sequestrants [4].
Who manufactures Praluent?
Praluent is manufactured by Sanofi [1].
What is Praluent used for?
Praluent is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [1]. It is typically prescribed for adults with certain types of high cholesterol, including those with inherited high cholesterol (heterozygous familial hypercholesterolemia) or those who have had a heart attack, stroke, or certain arterial conditions, and who are already taking a statin [1].
What are the side effects of Praluent?
Common side effects reported with Praluent include upper respiratory tract infection, influenza, and reactions at the injection site such as redness, pain, or itching [1]. Less common but potentially serious side effects can include allergic reactions [1].
How is Praluent administered?
Praluent is administered as an injection [1]. It is typically given once every two weeks or once a month [1].
What is the mechanism of action for Praluent?
Praluent is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) [2]. PCSK9 is a protein that binds to LDL receptors in the liver and promotes their degradation. By inhibiting PCSK9, Praluent increases the number of LDL receptors available to clear LDL cholesterol from the bloodstream [3].
What clinical data supports Praluent's effectiveness?
Clinical trials have demonstrated Praluent's ability to significantly reduce LDL cholesterol levels in various patient populations [2]. For example, studies have shown substantial reductions in LDL-C when Praluent is added to statin therapy in patients with heterozygous familial hypercholesterolemia or those with atherosclerotic cardiovascular disease [2].
Sources:
[1] https://www.praluent.com/
[2] https://www.drugpatentwatch.com/drug/praluent
[3] https://www.drugpatentwatch.com/mechanism/pcsk9-inhibitors
[4] https://www.drugpatentwatch.com/alternatives/cholesterol-lowering-drugs